GOLDSTEIN DOV A MD 4

What Happened

• Dov A. Goldstein, MD, Chief Financial Officer of BioAge Labs (BIOA), exercised stock options on Jan 16, 2026, resulting in the acquisition of 3,542 common shares. The exercise price paid was $4.38 per share, totaling $15,514. The filing also shows a corresponding disposition of 3,542 derivative instruments at $0, which reflects the option being converted/cancelled upon exercise (not a market sale).

Key Details

• Transaction date: 2026-01-16; Form 4 filed: 2026-01-21 (filed 5 days after the transaction; exceeds the typical 2-business-day Form 4 window).
• Acquired: 3,542 shares at $4.38 each — total cash paid $15,514.
• Disposed: 3,542 units at $0 (derivative) — represents cancellation/conversion of the option.
• Post-transaction total holdings: not specified in the filing.
• Footnote: The option vests 1/48th monthly, first vested Feb 1, 2025, then monthly thereafter, subject to continued service (Footnote F1).
• No indication of an immediate sale of the acquired shares, no 10b5-1 plan or tax-withholding settlement noted in the filing.

Context

• This was an exercise of vested options (transaction code M). The “disposed at $0 (derivative)” line is standard for reporting the surrender/conversion of the option itself and should not be read as a sale of the underlying shares. Exercises are acquisitions (purchase of shares) and are informative about an insider receiving stock, but do not by themselves indicate a buy/sell sentiment.